GET DAILY SIGNALSImunon (IMNN): Assessing the Path to a $16 Target and +2,400% Upside
Key Takeaways
- The central target of $16 is the arithmetic mean of four verified analyst price targets ($10, $12, $16 and $25), rounded from a calculated $15.75.
- With shares near $0.64, reaching $16 would require upside of roughly 2,400% — an exceptionally large move by any measure.
- The analyst range is unusually wide ($10 to $25), reflecting genuinely different views on the value of the IMNN-001 ovarian-cancer program.
- Key supports include a research collaboration with the National Cancer Institute (NCI) and encouraging Phase 2 overall-survival data.
- The principal risks are a disclosed going-concern warning, a short cash runway, ongoing dilution, and a pivotal readout still years away.
- For more detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages for this ticker.
Analyst Targets: A Range of Views
Four verifiable analyst targets inform the central figure. Maxim Group (analyst Jason McCarthy) carries a $10 target with a Buy rating, initiated in April 2026 and most recently maintained in late October 2026. Alliance Global Partners holds a $12 target, reiterated in September 2026. H.C. Wainwright maintains the high end at $25, reiterated in August 2026. Brookline Capital Markets has a $16 target, maintained in January 2026.
The arithmetic mean of these four targets is $15.75, which rounds to a clean $16 central target. The low-to-high range of $10 to $25 underscores how much these estimates diverge: the bullish case treats IMNN-001's survival benefit as a potential blockbuster, while the lower targets reflect the company's distressed capital position. Notably, several of these targets were set or reiterated before the company's November 12, 2026 third-quarter report, which added a going-concern disclosure. Analysts are uniformly Buy-rated, but that rating says more about the long-term science than about the near-term price path. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Position and the Road Ahead
Shares of IMNN traded near $0.64 as of the November 12, 2026 close, near the low end of a 52-week range of roughly $0.50 to $4.38. The company's market capitalization has shrunk to only a few million dollars, and the stock has fallen sharply over the past year. From $0.64, a move to $16 represents approximately 2,400% upside — a very large move that, in a clinical-stage micro-cap, is essentially a bet on a complete re-rating of the company's only lead program.
There is no revenue and no earnings multiple to anchor this stock. IMNN reported a third-quarter net loss of $3.8 million, or $0.64 per share, with cash and equivalents of about $4.0 million and an additional $5.0 million in restricted cash as of September 30, 2026. The path to any higher price therefore runs through successful trial execution, fresh financing, and — ultimately — clinical data that validates IMNN-001.
Supporting Factors for Potential Growth
The strongest support is scientific. Final Phase 2 (OVATION 2) data showed IMNN-001 added to chemotherapy improved median overall survival by about 14.7 months (45.1 versus 30.4 months). In September 2026 the company signed a Cooperative Research and Development Agreement (CRADA) with the NCI's Cancer Therapy Evaluation Program — reportedly the first gene-based immunotherapy selected for such a partnership — which offers non-dilutive validation and expanded development without diverting the company's own capital. A planned ThermoDox sale and a debt-to-preferred exchange modestly improve the balance sheet. If the OVATION 3 trial confirms the survival signal, the commercial upside in first-line ovarian cancer would be substantial relative to the company's current market value.
Risks and Challenges Ahead
The obstacles are severe. Management now discloses explicit going-concern doubt and has filed an S-1 for a proposed offering, signaling further dilution ahead. Unrestricted cash covers little more than one quarter of operating burn, and the pivotal readout is not expected until the early 2030s — enrollment completion is targeted for the first quarter of 2029, with a first interim analysis around the first quarter of 2030. Enrollment has moderated, and only a fraction of planned sites are active. Because the entire valuation rests on one binary trial outcome, any funding shortfall, enrollment delay, or negative data would challenge the case for higher prices, and analysts' targets predate some of these disclosures.
Technical Picture
From a technical standpoint, IMNN has been in a persistent downtrend, trading far below its 200-day moving average and near a 52-week low around $0.50. That low is the immediate support level to watch; a break below it would open fresh downside. On the upside, prior levels such as the $1.00 to $1.35 zone and the old highs near $4.38 represent distant resistance levels. With a sub-$1 share price, psychological and round-number levels matter more than usual, and the stock's extreme volatility and thin float make technical signals less reliable than fundamentals in this case.
What to Watch Going Forward
Analyst price targets generally reflect a roughly 12-month research horizon, though for a clinical-stage biotech whose defining catalyst is years away, the relevant horizon is effectively longer. Investors should monitor quarterly cash balances and burn, the terms of any new financing and its dilutive effect, enrollment pace and site activation in OVATION 3, updates on the NCI collaboration, and whether the ThermoDox sale to VoxelDox closes. Any interim analysis announcement or safety update could move the stock sharply. Upcoming earnings and financing disclosures are the most immediate items to watch. From what I see, monitoring these milestones closely helps frame the longer-term picture.
AI Daily Buy/Sell Signals
In my own process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor names like this one. The tool applies artificial intelligence to continuously track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, low-priced name like IMNN, it can help surface opportunities and track changing trends more efficiently alongside traditional research.
Final Assessment
The $16 central target for Imunon (IMNN) is an analyst-derived average — the mean of four targets spanning $10 to $25 — and it sits roughly 2,400% above the recent share price. That gap reflects both the genuine promise of IMNN-001's Phase 2 survival data and the reality that the stock has collapsed under funding pressure, a going-concern warning, and a readout that is still years away. The supportive case rests on science and NCI validation; the bearish case rests on cash, dilution, and time. Whether the shares approach $16 depends on financing terms, trial execution, and eventual data — none of which can be guaranteed. Investors should monitor the cash runway and OVATION 3 milestones above all else.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IMNN's Stochastic Oscillator stays in oversold zone for 10 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNN advanced for three days, in 128 of 178 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
IMNN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMNN as a result. In 94 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for IMNN turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 48 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMNN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.132) is normal, around the industry mean (3.498). P/E Ratio (-0.289) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. IMNN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the provision of oncology drug development services
Industry Biotechnology
Advertisement